24/7 Wall Street
10 Jul 2026, 19:37 UTC · 10w ago
Verdict
Headline leans bearish. We score IONS −1.00 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Ionis Pharmaceuticals' Phase 3 CARDIO-TTRansform study of eplontersen failed to meet its primary efficacy endpoint for ATTR-CM.
So whatThe failure of a key value driver in a Phase 3 trial directly led to a 21% weekly drop in stock price.
More negative than 99% of claims this week
Alnylam Pharmaceuticals' Amvuttra and BridgeBio's Attruby face reduced near-term competitive pressure following the eplontersen miss.
So whatA competitor's failure in the same therapeutic area typically increases the market share potential for remaining viable drugs.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 76% of claims this week
Ionis has three upcoming catalysts: full ESC trial data in August, a PDUFA for Alexander disease on September 22, and a hepatitis B decision on October 26.
So whatThese regulatory and data milestones provide the only immediate paths for stock recovery or further devaluation.
More positive than 64% of claims this week
Arrowhead Pharmaceuticals and Sarepta Therapeutics saw share price declines due to sector sympathy despite unrelated business operations.
More negative than 67% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
Shares plummeted after a Phase 3 clinical trial for eplontersen failed to meet its primary efficacy endpoint.
More negative than 83% of ticker scores this week
The stock fell due to sector sympathy despite having an unrelated business.
More negative than 83% of ticker scores this week
Shares declined in line with the general downturn in the RNA and rare-disease biotech sector.
More negative than 78% of ticker scores this week
Partnered with Ionis on the failed Phase 3 CARDIO-TTRansform study.
More positive than 50% of ticker scores this week
Despite a price dip, analysts view its product as a direct beneficiary of a competitor's clinical failure.
More positive than 44% of ticker scores this week
The stock bucked the general sector selloff and traded slightly higher.
Near neutral — 90% of ticker scores this week are stronger
Mentioned only as a comparison point for a private company investment opportunity.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
1d ago
More positive than 78% of relationship scores this week
[mutual] Alnylam's Amvuttra competes directly with Ionis's eplontersen in ATTR-CM.
More positive than 58% of relationship scores this week
[mutual] Biogen is a collaborator that co-develops multiple antisense assets with Ionis.
−30.9%
Price agrees with the score
$44.44 vs $64.27 close before publication (Jul 9) · not market-adjusted
IONS chart →
